Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome

Terminal complement inhibition is the standard of care for atypical hemolytic uremic syndrome (aHUS). The optimal duration of complement inhibition is unknown, although indefinite therapy is common. Here, we present the outcomes of a physician-directed eculizumab discontinuation and monitoring proto...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood Adv
Main Authors: Chaturvedi, Shruti, Dhaliwal, Noor, Hussain, Sarah, Dane, Kathryn, Upreti, Harshvardhan, Braunstein, Evan M., Yuan, Xuan, Sperati, C. John, Moliterno, Alison R., Brodsky, Robert A.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2021
Fag:
Thrombosis and Hemostasis
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7948299/
https://ncbi.nlm.nih.gov/pubmed/33683339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003175
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker